Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis
Yang-Xun Pan,Yi-Zhen Fu,Dan-Dan Hu,Qian Long,Jun-Cheng Wang,Mian Xi,Shi-Liang Liu,Li Xu,Meng-Zhong Liu,Min-Shan Chen,Yao-Jun Zhang
DOI: https://doi.org/10.3389/fonc.2020.01639
IF: 4.7
2020-10-29
Frontiers in Oncology
Abstract:<span><strong>Background:</strong> Both stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) are effective local treatments for hepatocellular carcinoma (HCC), but whether RFA is superior to SBRT is still controversial. Therefore, we performed a meta-analysis to compare the treatment outcomes of SBRT with RFA as curable or bridge intention.<strong>Methods:</strong> We searched online databases for studies that compared treatment outcomes for SBRT and RFA. Eligibility criteria included evaluation of local control, overall survival (OS), transplant rate, and post-transplant pathological necrosis.<strong>Results:</strong> As no randomized clinical trials met the criteria, 10 retrospective studies with a total of 2,732 patients were included. Two studies were in favor of SBRT in local control, two studies preferred RFA in OS, and others reported comparable outcomes for both. SBRT demonstrated significantly higher 1- and 3-year local control than RFA [odds ratio (OR) 0.42, 95% CI 0.24–0.74, <i>P</i> = 0.003; and OR 0.54, 95% CI 0.37–0.80, <i>P</i> = 0.002, respectively]. However, SBRT reported significantly shorter 1- and 2-year OS (OR 1.52, 95% CI 1.21–1.90, <i>P</i> = 0.0003; and OR 1.66, 95% CI 1.38–2.01, <i>P</i> < 0.00001, respectively). As bridge treatment, no significant difference was shown in transplant rate and post-transplant pathological necrosis rate (OR 0.57, 95% CI 0.32–1.03, <i>P</i> = 0.060; and OR 0.49, 95% CI 0.13–1.82, <i>P</i> = 0.290, respectively).<strong>Conclusions:</strong> This study demonstrates SBRT is able to complete a better local control for HCC than RFA, though the OS is inferior to RFA because of tumor burden or liver profiles of the enrolled studies. Well-designed, randomized, multicenter trials will be required to further investigate the conclusion.</span>
oncology